India to Kenya: Artemether Export Trade Route

To import finished pharmaceutical formulations containing Artemether into Kenya, compliance with the Pharmacy and Poisons Board (PPB) regulations is mandatory. As stipulated in the Pharmacy and Poisons (Registration of Health Products and Technologies) Rules, 2022, all health products must be registered with the PPB prior to importation, manufacture, or sale within Kenya.

Application Process:

1. Submission of Application: Applicants must complete Form 1, as outlined in the First Schedule of the 2022 Rules. The application should include comprehensive details of the product, including its composition, intended use, and manufacturing process.

2. Dossier Format: The PPB requires the submission of a Common Technical Document (CTD) or electronic Common Technical Document (eCTD) dossier. This dossier should encompass all necessary data on the product's quality, safety, and efficacy.

3. Local Representative: Non-Kenyan applicants or companies incorporated outside Kenya must appoint a local representative who is either a Kenyan citizen, a permanent resident, or a company incorporated in Kenya.

Timelines and Fees:

• Approval Timelines: The PPB's evaluation and approval process duration can vary based on the completeness and complexity of the submitted dossier.

• Registration Fees: Specific fees associated with product registration are determined by the PPB and may vary depending on the product category and application specifics.

GMP Inspection Requirements:

The PPB mandates Good Manufacturing Practice (GMP) compliance for all pharmaceutical products. Manufacturing facilities, including those in India, may be subject to GMP inspections by the PPB to ensure adherence to quality standards. These inspections are crucial for the approval of the product registration application.

Indian exporters of Artemether formulations must comply with the PPB's stringent quality and GMP standards to gain market authorization in Kenya.

GMP Certification Requirements:

• Compliance with International Standards: Manufacturers must demonstrate adherence to internationally recognized GMP standards, ensuring that products meet the required quality, safety, and efficacy benchmarks.

• PPB Inspections: The PPB reserves the right to conduct inspections of foreign manufacturing facilities to verify GMP compliance. These inspections are part of the product registration process and are essential for market approval.

Approved Indian Facilities:

The PPB maintains a register of approved health products and technologies, which includes information on authorized manufacturing facilities. Indian manufacturers seeking to export Artemether formulations to Kenya should ensure their facilities are listed and compliant with PPB standards.

Regulatory Actions:

In January 2025, the PPB issued a directive prohibiting the importation, distribution, sale, or handling of pharmaceutical products referencing the Indian Pharmacopoeia (IP). The Board emphasized that the IP is not recognized within Kenya's drug registration requirements, and products citing this standard are non-compliant with Kenyan regulations. (kenyans.co.ke)

Over the past 18 months, several regulatory changes have impacted the importation of pharmaceutical products into Kenya:

1. Ban on Indian Pharmacopoeia Products (January 2025): The PPB announced a ban on pharmaceutical products referencing the Indian Pharmacopoeia, citing non-compliance with Kenyan regulatory standards. This move aimed to ensure that all pharmaceutical products in the Kenyan market adhere to recognized quality and safety standards. (kenyans.co.ke)

2. Clarification on Product Registration (October 2025): The PPB addressed concerns regarding the alleged blocking of over 21,000 medical products from importation. The Board clarified that there was no blockade and emphasized the importance of periodic renewal of product authorizations every five years to ensure continued compliance with safety, efficacy, and quality standards. (the-star.co.ke)

These developments underscore the PPB's commitment to maintaining stringent regulatory oversight to safeguard public health in Kenya.

In 2024, Kenya imported Artemisinin-based medicaments valued at approximately USD 1.77 million. The demand for Artemether formulations in Kenya is primarily driven by the high prevalence of malaria, a leading cause of morbidity and mortality in the country. The World Health Organization (WHO) reported that in 2022, Kenya accounted for a significant portion of malaria cases in sub-Saharan Africa, underscoring the critical need for effective antimalarial treatments.

While Kenya has a growing pharmaceutical manufacturing sector, the domestic production of Artemether formulations remains limited. Consequently, the country relies heavily on imports to meet its demand for these essential medicines. The Kenya Medical Supplies Authority (KEMSA) is the primary procurer, accounting for the majority of Artemether imports, highlighting the government's commitment to ensuring the availability of antimalarial treatments.

Kenya maintains a 0% import duty rate for pharmaceutical products under HS code 30046000, including Artemether formulations. This exemption is part of the government's strategy to facilitate access to essential medicines. Additionally, pharmaceutical imports are typically exempt from Value Added Tax (VAT) in Kenya, further reducing the cost burden on healthcare providers and patients.

Kenya and India are both members of the World Trade Organization (WTO), which promotes trade liberalization among member countries. However, there is no specific Free Trade Agreement (FTA) between Kenya and India that affects pharmaceutical tariffs. There are no known anti-dumping duties imposed on Artemether imports from India, indicating a stable trade relationship in this sector.

India is the dominant supplier of Artemether formulations to Kenya, accounting for approximately 72.7% of India's total Artemether formulation exports, valued at USD 652.7 million. The top Indian exporters include IPCA Laboratories Limited, which alone exported USD 590.7 million worth of Artemether formulations to Kenya.

Other countries supplying Artemether to Kenya include China and various European Union (EU) member states. However, their market shares are significantly smaller compared to India. India's competitive pricing, coupled with established trade relations and the high quality of its pharmaceutical products, positions it favorably against competitors. Chinese and EU manufacturers often face higher production costs and regulatory hurdles, which can result in higher prices for their Artemether formulations.

The strong presence of Indian pharmaceutical companies in the Kenyan market is further reinforced by the strategic partnerships and procurement agreements with key Kenyan entities such as KEMSA. This collaboration ensures a steady supply of Artemether formulations, addressing the country's pressing need for effective malaria treatments.

India has solidified its position as a global leader in the production of generic pharmaceuticals, accounting for approximately 20% of the global supply by volume as of 2024. This dominance extends to the manufacturing of finished dosage forms containing Artemether, a critical antimalarial medication. The country's extensive network of pharmaceutical manufacturers, including over 130 facilities registered with the U.S. FDA for finished dosage forms, ensures a robust production capacity. These facilities adhere to stringent international quality standards, with many holding WHO-GMP certifications, underscoring their commitment to quality and safety. India's cost-effective manufacturing processes, driven by economies of scale and a skilled workforce, enable the production of Artemether formulations at competitive prices without compromising quality.

When comparing Artemether formulation exports, India offers a compelling balance of cost and quality. Chinese manufacturers have historically been significant players in the Artemether market; however, data from 2012 to 2014 indicates a decline in their export volumes and values, suggesting potential supply inconsistencies. European Union (EU) manufacturers are renowned for high-quality pharmaceuticals but often at higher price points due to stringent regulatory environments and higher production costs. In contrast, Indian Artemether formulations are competitively priced, with average import prices to Kenya around $0.24 per unit as of 2016. This pricing, coupled with India's adherence to international quality standards and a strong regulatory compliance record, makes Indian formulations both cost-effective and reliable.

The India-Kenya supply chain for Artemether formulations has demonstrated consistent reliability. India's pharmaceutical industry boasts substantial manufacturing capacities, with numerous facilities dedicated to the production of finished dosage forms. These facilities are equipped with advanced packaging and cold chain capabilities, essential for maintaining the stability of Artemether formulations, which are sensitive to temperature and humidity. While specific data on recent supply disruptions is limited, India's track record suggests a stable supply chain. Top Indian manufacturers continue to invest in capacity expansions and technological advancements to meet growing global demand, further enhancing supply reliability.

For Kenyan buyers sourcing Artemether formulations from India, the following strategies are recommended:

• Implement a Dual-Sourcing Strategy: Engage with multiple Indian manufacturers to mitigate risks associated with supply disruptions and ensure continuous availability.

• Negotiate Favorable Minimum Order Quantities (MOQs): While Indian suppliers often offer flexible MOQs, establishing clear agreements can optimize inventory management and cost efficiency.

• Establish Clear Payment Terms: Common payment terms in India-Kenya pharmaceutical trade include Letters of Credit (LC) and advance payments. Clearly define terms to ensure smooth transactions.

• Conduct Comprehensive Supplier Qualification: Evaluate potential suppliers based on WHO-GMP certifications, FDA approvals, and compliance with Kenyan regulatory requirements to ensure product quality and safety.

• Monitor Regulatory Compliance: Regularly review suppliers' adherence to international and local regulations to maintain a consistent supply of high-quality Artemether formulations.

By adopting these strategies, Kenyan buyers can secure a reliable and cost-effective supply of Artemether formulations from India, contributing to effective malaria management in the region.

Cost Estimates and Timeline:

• Audit Visits to India:
• Cost: Approximately $5,000 to $10,000 USD per audit, covering travel, accommodation, and professional fees.
• Timeline: Planning and execution typically require 4 to 6 weeks, including scheduling, travel, on-site inspection, and reporting.

By adhering to this comprehensive supplier qualification framework, Kenyan pharmaceutical companies can ensure the procurement of high-quality Artemether formulations, safeguarding public health and maintaining regulatory compliance.